Details of the Drug Combinations

General Information of This Drug (ID: DM13V0P)

Drug Name
Rivoceranib   DM13V0P
Indication
Disease Entry ICD 11 Status REF
Gastric adenocarcinoma 2B72 Phase 3 [1]
Sarcoma 2A60-2C35 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

22 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Rivoceranib + Temozolomide DC34XF9 Temozolomide Glioblastoma [3]
Rivoceranib + Rivoceranib DC6ENQ2 Rivoceranib Lung Adenocarcinoma [4]
Rivoceranib + Bupropion DCERO03 Bupropion Advanced Solid Tumor [5]
Rivoceranib + Paclitaxel DCDRO2D Paclitaxel Gastric Cancer [6]
Rivoceranib + Digoxin DCFD368 Digoxin Advanced Solid Tumor [7]
Rivoceranib + Docetaxel DCTW18V Docetaxel Metastatic Gastric Adenocarcinoma [8]
Rivoceranib + Oxaliplatin DCCD4F9 Oxaliplatin Gastroesophageal Junction Adenocarcinoma [9]
Rivoceranib + Oxaliplatin DCYPGPQ Oxaliplatin Gastric Cancer [10]
Rivoceranib + Vinorelbine DC257BZ Vinorelbine Advanced Triple-Negative Breast Cancer [11]
Rivoceranib + Topotecan DC41TML Topotecan Small Cell Lung Cancer [12]
Rivoceranib + Irinotecan DCCZD3J Irinotecan Esophageal Squamous Cell Carcinoma [13]
Rivoceranib + Temozolomide DCDGNOC Temozolomide Advanced Melanoma [14]
Rivoceranib + Irinotecan DCEIQD7 Irinotecan Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction [15]
Rivoceranib + Capecitabine DCGJFQZ Capecitabine Hepatocellular Carcinoma [16]
Rivoceranib + Capecitabine DCH9N6H Capecitabine Biliary Carcinoma [17]
Rivoceranib + Vinorelbine DCHAQ86 Vinorelbine Breast Cancer [18]
Rivoceranib + Paclitaxel DCHHL3X Paclitaxel Triple Negative Breast Cancer [19]
Rivoceranib + Etoposide DCIAAGG Etoposide Non-small Cell Lung Cancer [20]
Rivoceranib + Pemetrexed DCKV6KJ Pemetrexed Advanced Non-squamous Non-small-cell Lung Cancer [21]
Rivoceranib + Docetaxel DCSW81G Docetaxel Gastric Cancer [22]
Rivoceranib + Gemcitabine DCW6X2P Gemcitabine Metastatic Pancreatic Cancer [23]
Rivoceranib + Gefitinib DCVAMTB Gefitinib EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors [24]
------------------------------------------------------------------------------------
⏷ Show the Full List of 22 DrugCom(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT04072042) BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (BIOVAS). U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT03567135) Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma
4 ClinicalTrials.gov (NCT02691871) Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
5 ClinicalTrials.gov (NCT04457180) A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects
6 ClinicalTrials.gov (NCT03707028) Safety, Tolerability and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced GC or GEJ Cancer.. U.S. National Institutes of Health.
7 ClinicalTrials.gov (NCT04322552) A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects
8 ClinicalTrials.gov (NCT03071042) A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma
9 ClinicalTrials.gov (NCT03349866) A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction
10 ClinicalTrials.gov (NCT03472365) A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
11 ClinicalTrials.gov (NCT03254654) Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
12 ClinicalTrials.gov (NCT02980809) Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
13 ClinicalTrials.gov (NCT03251417) Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
14 ClinicalTrials.gov (NCT03422445) A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma
15 ClinicalTrials.gov (NCT03030937) Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA
16 ClinicalTrials.gov (NCT03114085) Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma
17 ClinicalTrials.gov (NCT03609489) A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma
18 ClinicalTrials.gov (NCT02768415) Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer
19 ClinicalTrials.gov (NCT03348098) Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer
20 ClinicalTrials.gov (NCT02733107) The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer
21 ClinicalTrials.gov (NCT03190239) Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients
22 ClinicalTrials.gov (NCT02596256) Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)
23 ClinicalTrials.gov (NCT02863367) A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer
24 ClinicalTrials.gov (NCT02824458) A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations